Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors

NCT04260009 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business reason unrelated to product safety

Conditions

Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma
Inflammatory Myofibroblastic Tumors
Solid Tumors

Interventions

DRUG: Brigatinib
DRUG: Brigatinib AAF

Sponsor

Takeda